Bavarian, mpox vaccine
WTAQ · 19h
Bavarian says mpox vaccine approved by EU regulator for adolescents
LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.
devdiscourse · 20h
EU Approves Use of Bavarian Nordic's Mpox Vaccine for Adolescents
Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as essential for containing an outbreak in parts of Africa, with the World Health Organization declaring mpox a global public health emergency.
The Pharma Letter · 1d
Gavi to secure Bavarian Nordic mpox vaccines for Africa
Denmark-based Bavarian Nordic and Gavi, the Vaccine Alliance yesterday announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN mpox vaccine (marketed as Jynneos or Imvanex) to be supplied to countries in Africa impacted by the mpox outbreak.
Politico Europe · 20h
EU drugs watchdog backs Bavarian Nordic’s mpox vaccine for adolescents
The European Commission has greenlit Bavarian Nordic’s mpox and smallpox vaccine for approval for kids aged 12 to 17. The European Medicines Agency carried out an expedited and positive review of the data in this patient group, the company said, with the Commission accepting the regulator's opinion.
Business Insider · 19h
Bavarian Nordic Gets EMA Approval Of Mpox Vaccine For Adolescents
(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX smallpox and mpox vaccine. This extends the current marketing authorization to include adolescents 12 to 17 years of age.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results